Table 1 Summary of key drug-drug interactions between HIV drugs and the licensed DAAs and dosing recommendations
From: Managing HIV/hepatitis C co-infection in the era of direct acting antivirals
Telaprevir | Boceprevir | |
|---|---|---|
ATV/r | Monitoring for hyperbilirubinemia recommended | Consider on a case by case basis if deemed necessary |
DRV/r/, FPV/r LPV/r | Not recommended | Not recommended |
EFV | Increase TVR to 1,250 mg q8h | Not recommended |
ETR | No dose adjustment needed | No dose adjustment needed |
RPV | No dose adjustment needed | No dose adjustment needed |
RAL | No dose adjustment needed | No dose adjustment needed |
TDF | Increased monitoring is warranted | No dose adjustment needed |